Swine Bibliography Centre
|
Support that keeps you updated for FREE  |
Bulletin No. 24 - Spring 2006
VirologyPMWS-PCV2-PCVD-PDNS
CHARREYRE C, BESEME S, BRUN A, BUBLOT M, LAPOSTOLLE B , SIERRA P, VAGANAY A
Protection of piglets against a PCV2 experimental challenge by vaccinating gilts with an inactivated adjuvanted PCV2 vaccine.
International Conference on Animal Circoviruses and Associated Diseases, European Society for Veterinary Virology, 2005
The efficacy of an inactivated oil adjuvanted porcine circovirus type 2 (PCV2) vaccine (CIRCOVAC®) was studied. Twenty-two specific pathogen free gilts, seronegative for PCV2, were randomly divided into 2 groups. Gilts form Group 1 were vaccinated with CIRCOVAC® and the other group served as control. The vaccine was intramuscularly administered to the gilts 5 and 2 weeks before breeding and 2 weeks before farrowing. The same number of piglets born to either vaccinated gilts or control gilts were challenged intra-nasally with 6.3 log 10 CCID 50 of PCV2 at 3 and 4 weeks of age. Some piglets born to control gilts were not challenged and kept as control. The subsequent analyses caried out included monitoring of clinical signs, rectal temperature, weight and PCV2 ORF2 ELISA antibodies during 4 weeks, estimation of seric and rectal viral load by quantitative PCR (Q-PCR), PCV2 immunochemical detection in mesenteric lymph nodes after necrospy. The results showed that gilt vaccination with CIRCOVAC® was very efficient in protecting the piglets. It was also shown that in piglets born to vaccinated gilts and infected with PCV2, the clinical signs, lesions and replication of the virus were significantly reduced.
